ScholarIQanswers from OpenAlex & ORCID
Natasha Rekhtman
ResearcherPublications, citations & collaboration network
Natasha Rekhtman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Natasha Rekhtman have?
ScholarIQindexed works
Natasha Rekhtman has 608 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Natasha Rekhtman have?
ScholarIQcitation count
Natasha Rekhtman has 41,590 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Natasha Rekhtman?
ScholarIQh-index
Natasha Rekhtman has an h-index of 85 in OpenAlex.
What is the i10-index of Natasha Rekhtman?
ScholarIQi10-index
Natasha Rekhtman has an i10-index of 188 in OpenAlex.
What is the ORCID of Natasha Rekhtman?
ScholarIQorcid
The ORCID for Natasha Rekhtman is on the source record.
What is the OpenAlex record for Natasha Rekhtman?
ScholarIQopenalex
The OpenAlex for Natasha Rekhtman is on the source record.
What are the most-cited papers on Natasha Rekhtman?
ScholarIQmost cited works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa Ho, Martin L. Miller, Natasha Rekhtman, André L. Moreira, Fawzia K. Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M. Forde, Jamie E. Chaft, Kellie N. Smith, Valsamo Anagnostou, Tricia R. Cottrell, Matthew D. Hellmann, Marianna Zahurak, Stephen C. Yang, David R. Jones, Stephen Broderick, Richard J. Battafarano, Moises J. Velez, Natasha Rekhtman, Zachary T. Olah, Jarushka Naidoo, Kristen A. Marrone, Franco Verde, Haidan Guo, Jiajia Zhang, Justina X. Caushi, Hok Yee Chan, John-William Sidhom, Robert B. Scharpf, James R. White, Edward Gabrielson, Hao Wang, Gary L. Rosner, Valerie W. Rusch, Jedd D. Wolchok, Taha Merghoub, Janis M. Taube, Victor E. Velculescu, Suzanne L. Topalian, Julie R. Brahmer, Drew M. Pardoll
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew G. Nicholson, Ming‐Sound Tsao, Mary Beth Beasley, Alain Borczuk, Élisabeth Brambilla, Wendy A. Cooper, Sanja Đačić, Deepali Jain, Keith M. Kerr, Sylvie Lantuéjoul, Masayuki Noguchi, Mauro Papotti, Natasha Rekhtman, Giorgio V. Scagliotti, Paul Van Schil, Lynette M. Sholl, Yasushi Yatabe, Akihiko Yoshida, William D. Travis
Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi, Francisco Sánchez-Vega, Konnor La, Walid K. Chatila, Philip Jonsson, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Jennifer L. Sauter, Natasha Rekhtman, Travis J. Hollmann, Kurt A. Schalper, Justin F. Gainor, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, Matthew D. Hellmann